The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.
The precision oncology company plans to use the proceeds to advance drugs in its pipeline, improve its RADR platform, and acquire new therapeutic assets.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The company provides a cloud-based platform to help cancer centers with tumor board management, survivorship care planning, and clinical decision support.
